Breast CancerALDRAMNCT05796219
Automated Low Dose Risk Assessment Mammography (ALDRAM)
A study testing Low dose mammogram in people with Breast Cancer, run by Manchester University NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
Breast cancer (BC) is the commonest cause of death in young women. Breast screening in women aged 35-45, at increased risk due to their family history, has been shown to improve survival. However, 80% of women who develop BC do not have a family history. Read more about this study
- Who is it for?
- Ages 30 to 45 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Breast Cancer
- What is being tested?
- Low dose mammogram
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 154 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 22 Feb 2019to 16 Feb 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 45 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Females with moderate to high risk of breast cancer, identified through and attending for annual review and mammography at the family history clinic, Nightingale Centre, Manchester
- Current age 30-45 years
- Capable of providing informed consent to a patient information sheet written in English
Who cannot join
- Prior breast cancer
- Prior breast augmentation or reduction
- Participation in the TARA-Prev study which included an additional mammogram and thus radiation dose
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Technical Development of Automated Low Dose Risk Assessment Mammography (ALDRAM) in Women Attending for Annual Mammography Through a Family History Clinic
Breast cancer (BC) is the commonest cause of death in young women. Breast screening in women aged 35-45, at increased risk due to their family history, has been shown to improve survival. However, 80% of women who develop BC do not have a family history. Numerous studies have shown that high mammographic density (MD) is one of the strongest risk factors for BC development. Full field digital mammography (FFDM) can be used to assess MD, however it is not recommended for population BC screening in those <40 years of age due to the concerns about the use of ionising radiation. Safe and accurate high throughput methods to quantify MD in young women are thus required to improve risk prediction and reduce BC mortality. This study aims to develop a low dose mammogram, with quantification of density using artificial intelligence, to facilitate high throughput risk assessment in young women. 600 women aged 30-45, previously identified as being at increased risk of BC and attending for annual mammography at The Nightingale Centre will be recruited. Participants will undergo FFDM of the right breast as usual, however, following acquisition of the craniocaudal (CC) view, the breast will remain compressed and the mammogram dose reduced by 90% to deliver a LD mammogram. This process will be repeated for the right medio-lateral oblique (MLO) view. The left breast FFDM will proceed as normal. It is estimated that each extra exposure will take 1-2 minutes only. Deep machine learning methods will be used to define the relationship between standard FFDM views and their low dose counterparts and determine which view (CC vs MLO) provides the best correlation to be taken forward to the next stage of the research.
Read the detailed description
The more prolonged compression of the breast required to acquire the LD images may cause some additional breast discomfort. However, in a similar study in The Netherlands only 1% of women could not tolerate the procedure.
Participants will receive an extra dose of ionising radiation amounting to 20% of the radiation dose of a single FFDM view (of which 4 are usually taken, 2 on each breast). The risks associated with this are described in section B and entered into the PIS.
The research question for this study is whether an automated, low dose mammogram can be developed to provide an accurate assessment of mammographic density, and thus breast cancer risk, in women aged 30-45.
The two key objectives are:
- To develop machine learning methods for automated quantification of mammographic density using low dose mammograms in a study of 600 women attending for annual Full Field Digital Mammography (FFDM).
- To validate Automated Low Dose Risk Assessment Mammography (ALDRAM) against automated FFDM assessment that has been shown to predict BC risk.
Breast cancer is the commonest of all causes of death in young women. Currently the only factor triggering referral to risk assessment clinics is the presence of a family history. Although this is known to confer increased risk, only 20% of young women who develop BC actually have such a family history of the disease. Thus 80% of cases come 'out of the blue' and methods to assess risk in the general population are required if we are to improve survival (screening in those at increased risk aged 35-45 has been shown to reduce mortality). High mammographic density has been shown in multiple studies to confer significantly increased risk of BC, however population screening with full field digital mammograms is not recommended in those <40 primarily due to the reduced sensitivity and use of a moderate doses of ionising radiation. There is thus an urgent need for safe, high throughput, techniques to accurately define mammographic density in young women - the purpose of this study. Following consent and initial Case Report Form (CRF) completion, mammography will commence as standard. The right breast craniocaudal (CC) view will be performed first and the steps below followed:
- The breast will be positioned as standard for the CC view.
- The Automatic Optimisation of Parameters (AOP; also known as Automatic Exposure Control (AEC)) will be performed for target, filter, Peak KiloVoltage (kVp) and MilliAmpere second (mAs) selection for Full Field Digital Mammography (FFDM).
- The full field CC view will be performed as standard.
- The breast will remain compressed whilst the radiographer manually reduces the mAs by 90% or to the minimum value of 4 mAs (the machine does not deliver less than 4 mAs). No other parameters will be changed. A repeat CC exposure at this reduced dose will be performed.
- The machine will be reset to automatic and the subsequent mediolateral oblique (MLO) view will be obtained and the low dose view performed again as above.
- The left breast CC and MLO views will then be obtained as standard.
- This concludes the woman's participation in the study. The images from the low dose and FFDMs will then be processed to determine whether mammographic density from low dose mammograms correlates with that from FFDM and what modifications are required to automated algorithms for future studies.
- Conditions
- Breast Cancer
- Being tested
- Low dose mammogram
- Keywords
- Low dose mammogram
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low dose mammogramRadiation
Low dose mammogram
| Study group | Role | What they receive |
|---|---|---|
| Low dose mammogram | Other | Low dose mammo to compare with standard mammo Receives: Radiation: Low dose mammogram |
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation between full dose and low dose percent mammographic density estimates
Full dose and Low dose mammograms will be analysed using an established AI technique, the predicted Visual Analogue Score (pVAS), to determine the percent mammographic density (%MD). Correlation between the full and low dose image derived %MD across the whole study population will be assessed using Pearson correlation coefficient.
Measured: The low dose mammogram will be taken immediately after the full dose exposure, under the same breast compression.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Apr 2023
- Study start22 Feb 2019
- Primary completion5 May 2020
- Study completion16 Feb 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- The research question for this study is whether an automated, low dose mammogram can be developed to provide an accurate assessment of mammographic density, and thus breast cancer risk, in women aged 30-45.
- Masking
- None (open label)
- Enrolment
- 154 participants (actual)
Sponsor and investigators
- Lead sponsor
- Manchester University NHS Foundation Trust
- Sponsor type
- Other government
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05796219
- Sponsor's protocol ID
- B00394
- Acronym
- ALDRAM
- Status last verified
- Mar 2023
- First submitted
- 22 Mar 2022
- Last updated
- 3 Apr 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Share Protocol
Study at a glance
From the registry record, last updated by the sponsor on 3 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Technical Development of Automated Low Dose Risk Assessment Mammography (ALDRAM) in Women Attending for Annual Mammography Through a Family History Clinic
- ClinicalTrials.gov ID
- NCT05796219
- Acronym / sponsor ID
- ALDRAM / B00394
- Conditions
- Breast Cancer
- Keywords
- Low dose mammogram
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 154 participants (actual)
- Lead sponsor
- Manchester University NHS Foundation TrustOther government
- Study start
- 22 Feb 2019 (actual)
- Primary completion
- 5 May 2020 (actual)
- Study completion
- 16 Feb 2023 (actual)
- First posted
- 3 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Breast cancer (BC) is the commonest cause of death in young women. Breast screening in women aged 35-45, at increased risk due to their family history, has been shown to improve survival. However, 80% of women who develop BC do not have a family history. Numerous studies have shown that high mammographic density (MD) is one of the strongest risk factors for BC development. Full field digital mammography (FFDM) can be used to assess MD, however it is not recommended for population BC screening in those <40 years of age due to the concerns about the use of ionising radiation. Safe and accurate high throughput methods to quantify MD in young women are thus required to improve risk prediction and reduce BC mortality. This study aims to develop a low dose mammogram, with quantification of density using artificial intelligence, to facilitate high throughput risk assessment in young women. 600 women aged 30-45, previously identified as being at increased risk of BC and attending for annual mammography at The Nightingale Centre will be recruited. Participants will undergo FFDM of the right breast as usual, however, following acquisition of the craniocaudal (CC) view, the breast will remain compressed and the mammogram dose reduced by 90% to deliver a LD mammogram. This process will be repeated for the right medio-lateral oblique (MLO) view. The left breast FFDM will proceed as normal. It is estimated that each extra exposure will take 1-2 minutes only. Deep machine learning methods will be used to define the relationship between standard FFDM views and their low dose counterparts and determine which view (CC vs MLO) provides the best correlation to be taken forward to the next stage of the research.
Detailed description
The more prolonged compression of the breast required to acquire the LD images may cause some additional breast discomfort. However, in a similar study in The Netherlands only 1% of women could not tolerate the procedure.
Participants will receive an extra dose of ionising radiation amounting to 20% of the radiation dose of a single FFDM view (of which 4 are usually taken, 2 on each breast). The risks associated with this are described in section B and entered into the PIS.
The research question for this study is whether an automated, low dose mammogram can be developed to provide an accurate assessment of mammographic density, and thus breast cancer risk, in women aged 30-45.
The two key objectives are:
- To develop machine learning methods for automated quantification of mammographic density using low dose mammograms in a study of 600 women attending for annual Full Field Digital Mammography (FFDM).
- To validate Automated Low Dose Risk Assessment Mammography (ALDRAM) against automated FFDM assessment that has been shown to predict BC risk.
Breast cancer is the commonest of all causes of death in young women. Currently the only factor triggering referral to risk assessment clinics is the presence of a family history. Although this is known to confer increased risk, only 20% of young women who develop BC actually have such a family history of the disease. Thus 80% of cases come 'out of the blue' and methods to assess risk in the general population are required if we are to improve survival (screening in those at increased risk aged 35-45 has been shown to reduce mortality). High mammographic density has been shown in multiple studies to confer significantly increased risk of BC, however population screening with full field digital mammograms is not recommended in those <40 primarily due to the reduced sensitivity and use of a moderate doses of ionising radiation. There is thus an urgent need for safe, high throughput, techniques to accurately define mammographic density in young women - the purpose of this study. Following consent and initial Case Report Form (CRF) completion, mammography will commence as standard. The right breast craniocaudal (CC) view will be performed first and the steps below followed:
- The breast will be positioned as standard for the CC view.
- The Automatic Optimisation of Parameters (AOP; also known as Automatic Exposure Control (AEC)) will be performed for target, filter, Peak KiloVoltage (kVp) and MilliAmpere second (mAs) selection for Full Field Digital Mammography (FFDM).
- The full field CC view will be performed as standard.
- The breast will remain compressed whilst the radiographer manually reduces the mAs by 90% or to the minimum value of 4 mAs (the machine does not deliver less than 4 mAs). No other parameters will be changed. A repeat CC exposure at this reduced dose will be performed.
- The machine will be reset to automatic and the subsequent mediolateral oblique (MLO) view will be obtained and the low dose view performed again as above.
- The left breast CC and MLO views will then be obtained as standard.
- This concludes the woman's participation in the study. The images from the low dose and FFDMs will then be processed to determine whether mammographic density from low dose mammograms correlates with that from FFDM and what modifications are required to automated algorithms for future studies.
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- The research question for this study is whether an automated, low dose mammogram can be developed to provide an accurate assessment of mammographic density, and thus breast cancer risk, in women aged 30-45.
| Arm | Type | Receives |
|---|---|---|
| Low dose mammogram | Other | Radiation: Low dose mammogramLow dose mammo to compare with standard mammo |
Who may qualify
- Ages
- 30 to 45 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Females with moderate to high risk of breast cancer, identified through and attending for annual review and mammography at the family history clinic, Nightingale Centre, Manchester
- Current age 30-45 years
- Capable of providing informed consent to a patient information sheet written in English
Key exclusion criteria (3 listed)
- Prior breast cancer
- Prior breast augmentation or reduction
- Participation in the TARA-Prev study which included an additional mammogram and thus radiation dose
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low dose mammogramLow dose mammogram | Radiation | Low dose mammogram |
Primary outcome
Correlation between full dose and low dose percent mammographic density estimates
Time frame: The low dose mammogram will be taken immediately after the full dose exposure, under the same breast compression.
Full dose and Low dose mammograms will be analysed using an established AI technique, the predicted Visual Analogue Score (pVAS), to determine the percent mammographic density (%MD). Correlation between the full and low dose image derived %MD across the whole study population will be assessed using Pearson correlation coefficient.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Apr 2023.
- Individual participant dataSharing planned: Undecided. Share Protocol
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Low dose mammogram in people with Breast Cancer, run by Manchester University NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation between full dose and low dose percent mammographic density estimates (time frame: The low dose mammogram will be taken immediately after the full dose exposure, under the same breast compression.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2023.